Evaluation of a New Multiparameter Brain Probe for Simultaneous Measurement of Brain Tissue Oxygenation, Cerebral Blood Flow, Intracranial Pressure, and Brain Temperature in a Porcine Model

Marius M. Mader1,2, Anna Leidorf1, Andreas Hecker1, Axel Heimann1, Petra S. M. Mayr1, Oliver Kempski1, Beat Alessandri1* and Gabriele Wöbker3

© 2018 The Author(s)

Abstract

Background: A novel multiparameter brain sensor (MPBS) allows the simultaneous measurement of brain tissue oxygenation (ptiO2), cerebral blood flow (CBF), intracranial pressure (ICP), and brain temperature with a single catheter. This laboratory investigation evaluates the MPBS in an animal model in relation to established reference probes.

Methods: The study group consisted of 17 juvenile male pigs. Four MPBS and four reference probes were implanted per pig and compared simultaneously. The measured parameters were challenged by standardized provocations such as hyperoxia, dobutamine, and norepinephrine application, hypercapnia and hypoxia in combination with and without a controlled cortical impact (CCI) injury. Mean values over 2 min were collected for predefined time points and were analyzed using Bland–Altman plots.

Results: The protocol was successfully conducted in 15 pigs of which seven received CCI. ICP and ptiO2 were significantly influenced by the provocations. Subtraction of MPBS from reference values revealed a mean difference (limits of agreement) of 3.7 (−20.5 to 27.9) mm Hg, −2.9 (−7.9 to 2.1) mm Hg, and 5.1 (−134.7 to 145.0) % for ptiO2, ICP, and relative CBF, respectively.

Conclusions: The MPBS is a promising measurement tool for multiparameter neuromonitoring. The conducted study demonstrates the in vivo functionality of the probe. Comparison with standard probes revealed a deviation which is mostly analogous to other multiparameter devices. However, further evaluation of the device is necessary before it can reliably be used for clinical decision making.

Keywords: Neurophysiological monitoring, Swine, Brain injuries, Intracranial pressure, Oxygen, Laser Doppler flowmetry

*Correspondence: beat.alessandri@unimedizin-mainz.de

1 Institute for Neurosurgical Pathophysiology, University Medical Center of the Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz, Germany

Full list of author information is available at the end of the article

The MPBS is currently neither CE marked, nor FDA approved for clinical use. The manufacturers are reviewing plans to make the device available for routine clinical use in the future.
Introduction

Intensive care treatment of patients with traumatic brain injury (TBI) aims at maintaining an adequate brain perfusion and oxygenation to prevent secondary brain damage [1]. A continuous neuromonitoring via intraparenchymal sensor allows assessment of pathological changes, prediction of outcome, and guidance throughout the treatment. Key parameters are particularly intracranial pressure (ICP) and brain tissue oxygen tension (pTiiO2) since several studies could show a benefit if monitored [2–9].

Most probes in clinical use measure a single parameter only. Consequently, multiparametric monitoring usually requires simultaneous implantation of several probes with an additional risk of complications like bleeding or infection. The development of multiparameter probes addresses this issue. Until recently, the Neurovent-PTO monitor (Raumedic; dimension: 5F) is based on the same technology. One Neurovent probe was implanted per pig to a depth of 15 mm and fixated with bone wax (Figs. 1, 2).

The main goal of this study was to evaluate the functionality of the MPBS in comparison with well-established reference probes in a pig model under control and in order to increase heterogenicity of collected data under post-traumatic conditions. An additional goal was to confirm a previously described testing protocol that challenges different parameters in order to standardize the evaluation process for new sensors [13].

Methods

All experiments were approved by the ethical committee for Animal Use and Care and performed according to national guidelines for animal experiments. Seventeen juvenile male pigs at the age of 3–4 months (German breed 29–32 kg) were used. Anesthesia was induced via intramuscular injection of ketamine (15 mg/kg) and azaperone (3 mg/kg) followed by intravenous administration of 10 ml thiopental (25 mg/ml; Trapanal, Nycomed). Continuous intravenous application of thiopental (10–15 mg/kg bw/h) and piritramide (0.2–0.3 mg/kg bw/h; Dipidolor, Janssen-Cilag Pharmaceuticals Inc.) maintained sedation. All animals were intubated (Lo-Contour Murphy, Mallinckrodt; i.d.o.d. 6.0/5.5 mm) and mechanically ventilated with a fraction of inspired oxygen (FiO2) of 0.27 (900B; Siemens-Elema AB). Body temperature was kept at a physiological level (Homeothermic Blanket Systems, Harvard Apparatus). Cannulation of femoral artery, femoral vein, and jugular vein permitted monitoring of blood pressure, blood gases, and hemodynamic parameters via PiCCO plus (PULSION Medical Systems AG, München, Germany).

The head was fixed in a stereotactic frame, and the skull was exposed. Thereafter, four burr holes per hemisphere were drilled through the parietal bone. Nine animals additionally received a left parietotemporal craniectomy 1 cm lateral to the sagittal suture with a diameter of 3 cm. A controlled cortical impact (CCI) device was brought in position above the intact dura for later trauma induction. The dura underneath the CCI device was opened with a needle. Four MPBS and four reference probes were implanted per pig to a depth of 15 mm and fixated with bone wax (Figs. 1, 2).

The MPBS consists of four units measuring oxygen tension, temperature, pressure, and blood flow, which are arranged along a rigid steel shaft (length 14.5 mm; diameter max. 1.67 mm [5F], tip 0.96 mm) (Fig. 3).

pTiiO2 measurement is based on oxygen quenching. A fluorophore within a silicone matrix absorbs light pulsed through a fiber-optic light guide. Since resulting fluorescence lifetime is inversely proportional to the concentration of dissolved oxygen, oxygen tension can be calculated. This process is temperature dependent, but is corrected by the integrated thermocouple, which allows the measurement of brain temperature. No oxygen is consumed. The sensor was already precalibrated by the manufacturer. Two Licox probes (Integra Neuroscience) per pig were used as reference probes for pTiiO2 and temperature. According to manufacturer information, the Licox oxygen probe and temperature probe have a diameter at tip of 0.6 and 0.8 mm, respectively. The Licox pTiiO2 sensor is a Clark-type electrode: The reduction of oxygen results in a current proportional to the oxygen tension, and a small amount of oxygen is consumed.

The MPBS contains a Millar solid-state Micro-Electro-Mechanical Systems sensor for pressure measurement. A piezoresitive bridge assembly transduces pressure into a gaugeable current. The Neurovent ICP reference probe (Neurovent-P, Raumedic; dimension: 5F) is based on the same technology. One Neurovent probe was implanted per animal.

The MPBS measures CBF via LDF. This sensor consists of two optical light guides, one for laser emission and one for collection of light. Laser light is scattered by immobile tissue as well as moving particles such as erythrocytes. The difference in the reflected wavelengths results in a laser Doppler shift which is detected and calculated as a relative arbitrary unit blood perfusion unit. One thermal diffusion reference probe (Bowman Perfusion Monitor, Hemedex) was used per pig, which calculates CBF by determination of the power dissipated by a heated thermometer and has a diameter of 1 mm [14].
All ICP sensors were calibrated before implantation. Additionally, Licox probes were calibrated and all ptiO2 sensors were in vitro tested in oxygenated water and deoxygenated solution (0.26 g Borax (sodium tetraborate, Nr. 6306, Fa. Merck), 1.63 g sodium sulfite (Nr. 6657, Fa. Merck), 1000 ml dest. water) either before implantation or after explantation.

After sensor implantation (15 mm insertion depth) and an equilibration period of 60–120 min, the study protocol consisting of optional CCI as well as pharmaceutical and respiratory manipulations was started (Fig. 1). The protocol was based on a previously published methodological groundwork [13]. After surveying baseline values, the nine craniectomized pigs underwent CCI. Intention for CCI was to induce an additional aspect of interindividual heterogeneity including alterations in cerebrovascular autoregulation. Trauma parameters were a velocity of 3.5 m/s, depth of 10 mm, and duration of 200 ms. Afterward, the craniotomy was closed with an alginate plastic. Effects of the trauma were observed over a period of 30 min before further provocations began. Respiratory challenges included hyperoxygenation (pao2 > 400 mm Hg; 15 min), hypercapnia via apnoeic oxygenation for 15 min (pacO2 > 75 mm Hg) and hypoxia by ventilating with an air/N2 mixture for approximately 6 min (pO2 < 35 mm Hg). Pharmaceutical manipulations were comprised of an administration of dobutamine (5/10/15 µg/kg/h; 3 × 15 min; Carinopharm GmbH) and norepinephrine (0.2/0.4/0.6 µg/kg/h; 3 × 15 min; Arterenol, Sanofi-Aventis). There was an at least 15-min recovery period between the respective challenges.

Data were recorded at 1 Hz using LabChart Software (ADInstruments) and analyzed with Sigmaplot (Systat Ldt.). Mean values of 2 min were calculated before each challenge and every 5 min (every 2 min during hypoxia) during the challenges. The averaged values were then analyzed in Bland–Altman plots [15, 16]. Line plots were created comparing mean values of MPBS and reference probes. Applying an α-level of 0.05, Mann–Whitney rank-sum test or t test depending on normality and equal variance was used to check for statistical differences.
Results
Animals and Measurements
Fifteen of the 17 animals were analyzed. Two animals of the CCI group died during the experiment, one from pneumothorax and one related to CCI. Eight control and seven CCI animals were used for probe evaluation. Given that four MPBS were implanted per pig and the protocol consisted of five challenges, 20 recorded challenges were obtained per animal.

The different modules were checked for predefined inappropriate reactivity or implausible values. This was classified as device malfunctioning, and respective challenges were excluded. Moreover, artificially altered measurements by manipulation of the setup (e.g., accidental probe movement) during the protocol were excluded. 20.2% (pTiO₂), 15.1% (ICP), and 12.8% (CBF) of measurements were affected.
The Hemedex probe exhibited multiple periods of measurement interruption per experiment. These were more frequent the further the protocol had progressed. In total, 21.4% of single measurement points distributed over 50 different challenges (68.5% of all challenges) were affected. Figure 7 (supplementary material) demonstrates exemplarily CBF values measured by MPBS and Hemedex in an individual animal of the control group.

No difficulties were experienced with MPBS probe implantation. Handling was equivalent to the similarly sized Neurovent-P probe. No major bleeding was macroscopically observed in cerebral cross sections after the experiment.

**In Vitro Measurements**

The mean (±SEM) in vitro measurements of the ptiO2 sensors were 151.7 ± 4.3 mm Hg (MPBS) and 149.0 ± 1.8 mm Hg (Licox) in oxygen-enriched solution after equilibration. There was a statistically significant difference between the measurements in the oxygen-deprived solution (0.5 ± 0.1 mm Hg (MPBS), 1.2 ± 0.3 mm Hg (Licox), \( p = 0.031 \)).

**Bland–Altman Plots**

As shown in the Bland–Altman plots (Fig. 4), subtraction of MPBS from reference values revealed a mean difference of 3.7 mm Hg, −2.9 mm Hg, and 5.1% for ptiO2, ICP, and relative CBF, respectively. Accordingly, MPBS measured higher ICP but lower ptiO2 and CBF values than the reference probes.

**PtIO2 Key Challenges**

Figure 5 shows mean values (±SEM) of MPBS in comparison with Licox probes in key challenges for ptiO2 in the control group. Both ptiO2 modules demonstrated a significant rise in ptiO2 from 15.8 ± 3.3 mm Hg (MPBS) and 15.6 ± 2.0 mm Hg (Licox) to 27.6 ± 5.3 mm Hg (MPBS; 74.7% increase, \( p = 0.041 \)) and 30.4 ± 4.5 mm Hg (Licox; 94.9% increase, \( p = 0.011 \)) after 15 min of hyperoxia.

There was a mean increase in arterial partial pressure of oxygen.
oxygen (PaO₂) from 147.6±3.1 to 527.8±35.5 mm Hg. Hypoxia led to a decrease in PaO₂ from 130.7±25.6 to 23.1±10.6 mm Hg. The values measured by MPBS and Licox were 13.6±2.7 and 15.1±2.3 mm Hg at baseline, 3.8±1.2 mm Hg (72.1% decrease, p<0.001) and 3.8±0.6 mm Hg (74.8% decrease, p<0.001) after 6 min, respectively. This demonstrates a significant decline in ptiO₂.

**ICP Key Challenges**

Figure 6 demonstrates the mean ICP values (±SEM) of MPBS and Neurovent for key ICP provocations in the control group. Hypercapnia resulted in a rise in arterial partial pressure of carbon dioxide (PaCO₂) from 43.1±1.7 to 103.0±2.8 mm Hg after 15 min. ICP reacted with a significant increase from 11.6±1.0 mm Hg (MPBS) and 8.0±2.0 mm Hg (Neurovent) to 23.7±1.6 mm Hg (MPBS; 104.3% increase, p<0.001) and 19.6±2.1 mm Hg (Neurovent; 145.0% increase, p=0.004). Hypoxia also led to a significant increase in ICP from 7.9±0.9 mm Hg (MPBS) and 5.0±1.3 mm Hg (Neurovent) to 17.5±1.6 mm Hg (MPBS; 121.5% increase, p<0.001) and 14.0±2.3 mm Hg (Neurovent; 180.0% increase, p=0.004) after 6 min.

**ptiO₂ Agreement Matrix**

A dichotomized agreement matrix including a total of 890 ptiO₂ measurement points of both control and CCI group revealed an observed agreement between MPBS and Licox of 0.63 and 0.68 applying thresholds of 15 or 20 mm Hg, respectively (Table 1, supplementary material). Deviating results were mainly caused by MPBS indicating a value below and Licox a value above the threshold. The other way around occurred only in 5.8 and 7.2% of cases applying thresholds of 15 or 20 mm Hg, respectively.

**Effect of CCI on CBF During Pharmacological Challenges**

In relation to the initial baseline of the protocol, relative CBF as mean±SEM of the CCI group was 98.8±3.6% (MPBS) and 89.6±7.4% (Hemedex) before dobutamine application. After 15 min of 15 µg/kg/h dobutamine application, relative CBF was 105.3±6.9% (MPBS) and 104.7±8.3% (Hemedex), which equals a nonsignificant rise (MPBS: p=0.482, Hemedex: p=0.198).

CBF values were 104.0±7.1 and 80.4±10.7% before norepinephrine challenge and increased to 113.5±9.2 and 87.2±9.6% under 15 min of 0.6 µg/kg/h norepinephrine application for MPBS (p=0.431) and Hemedex (p=0.501), respectively.

**Temporal Changes in Measurement**

Figure 8 (supplementary material) demonstrates the mean (±SEM) of the differences between the values of the initial baseline and the baseline before hypoxia for different sensors of MPBS and respective reference probes in the control group. The difference was 2.5±2.5 mm Hg (MPBS) and 0.5±2.2 mm Hg (Licox) for ptiO₂, 0.5±0.8 (MPBS) and 1.1±1.1 mm Hg (Raumedic) for ICP, and −15.5±12.7% (MPBS) and 23.2±20.1% (Hemedex) for CBF measurement. There was no statistically significant difference between respective MPBS and reference probe deviations.

---

*Fig. 6 Key provocations for ICP measurement evaluation. The line plots show mean values (±SEM) of all MPBS and the Neurovent probe during key ICP provocations for control animals. Asterisks (*) mark significant differences between the baseline and endpoint values and diamonds (◊) between the two devices (p<0.05). B, baseline*
Discussion
The Relevance of Multiparametric Intraparenchymal Neuromonitoring

Several studies were conducted to show a reduced mortality linked to sole ICP monitoring [2–5]. However, other trials reported unchanged or even elevated mortality as well as prolonged duration of mechanical ventilation when ICP monitoring and guided therapy were applied [17–19]. Such conflicting results might be due to cerebral hypoxia despite an apparently adequate CPP [20]. By adding ptiO2 measurement to ICP monitoring and keeping ptiO2 values above 25 mm Hg, mortality could be reduced [21]. Some studies confirmed reduced mortality and morbidity in relation to a ptiO2-guided treatment [6–9]. However, missing beneficial effects on the outcome have been published as well [22, 23].

Simultaneous monitoring of ICP and ptiO2 with a single catheter is a substantial progress. This prevents additional complications and effort, which go along with implantation of several different probes. Combining this lineup with direct CBF measurement, e.g., LDF, can be a useful addendum for ischemia detection [24, 25]. Monitoring the described parameters simultaneously draws a more complete picture of the pathological changes taking place in brain-injured patients and can lead to better adjusted therapeutical strategies.

A Methodical Approach to the Standardized Evaluation of Multiparameter Probes

The evaluation of a new measurement device is based on comparison with an already established technology. In case of multiparameter brain sensors, different reference probes are necessary for the respective parameters. For translational purposes, proper function of tested sensors should ideally be evaluated in vivo during standardized physiological challenges under both physiological and pathologic conditions.

Licox and Neurovent-P are well-established probes considered as ‘gold standard’ and adequate references since these devices have been well known by clinicians for years [26, 27]. Therefore, we preferred these probes over the relatively new Neurovent-PT0, which is also a multiparametric device for ICP and ptiO2 [10]. The already published evaluations of Neurovent-PTO also used Licox probes as Ref. [10, 11, 28]. Location of probes was mainly influenced by the location of the craniectomy. Ipsilateral probes were positioned as close as possible to the traumatic area with enough space between them to minimize interference. Therefore, Neurovent-P probe was implanted on the contralateral side since ICP is a more systemic parameter. The two additional MPBS and second Licox probe were inserted contralateral to allow for hemispheric-specific analysis.

CCI was performed with the intention to induce an additional factor of heterogeneity between different animals including alterations in cerebrovascular autoregulation. The validity of the study should have been increased by a broader range of values being available for Bland–Altman analysis. Moreover, the translational value has been enhanced with CCI as a model for a clinically relevant condition.

Two pharmacological challenges were included in the protocol mainly for CBF manipulation. Mean arterial pressure (MAP) dipped under dobutamine, whereas stable to slightly increased MAP was observed during nor-epinephrine application. An increase in cardiac index (CI) and heart rate was induced by both drugs. However, CCI animals did not show the expected major changes in CBF. Possibly, CCI was not severe enough to impair arterial autoregulation sufficiently or probe location was too distant.

Key provocations for ptiO2 were hyperoxia and hypoxia. As expected, alterations of PaO2 led to a significant increase or decrease in ptiO2. This was detected by both MPBS and Licox. ICP was mainly influenced by hypercapnia and hypoxia. Increased PaCO2 as well as decreased PaO2 acted as vasodilative agents leading to a significant rise in ICP which was also noticed by both monitoring devices.

Generally, methodical principles and considerations which were described before are now confirmed with an increased number of animals and measurements [13]. The animal model and protocol generally provide a feasible basis for future testing of neuromonitoring devices.

Handling of the MPBS

The specification of the MPBS dimension is comparable to the well-established Neurovent-P probe, and insertion procedure was similar. The recently clinically induced multiparametric device Neurovent-PTO is stated with the same dimension. Since the non-flexible steel shaft is equally in length to the planned insertion depth in the utilized animal model, this was no hindering factor. In clinical application, a bolt device would seem to be feasible. No clinically relevant complications like intraparenchymal hemorrhage associated with MPBS insertion were registered.

Evaluation of the ptiO2 Sensor

The ptiO2 and temperature sensors were compared with the well-established Licox probe (Integra Neuroscience) [27]. In our experiments, average in vivo ptiO2 values measured by Licox were 3.73 mm Hg higher than MPBS values. Certainly, attention should be paid to relatively broad limits of agreement. In comparison, measurement
differences of other multiparameter probes to reference sensors seem to be similar:

The Neurovent-PTO monitor (Raumedic) combines the measurement of ICP, ptiO2—also by oxygen quenching—and temperature. In the literature, evaluation of this catheter showed higher mean ptiO2 values compared to Licox [10, 11, 28]. Differences were 6.3 mm Hg in a porcine model, 1.24 mm Hg (CI −25.1 to 22.6 mm Hg) in intensive care patients, and 6.1 mm Hg (CI −32.1 to 20.0 mm Hg) in FiO2- and MAP-challenged patients. An unequal sampling area size (Licox: 13 mm²; Neurovent-PTO: 22 mm²) and the oxygen consumption of the Clark electrode of the Licox probe were provided as possible explanations for higher Neurovent values. However, in our experiments, MPBS values were lower than Licox values even though MPBS and Neurovent-PTO have a similar technology, and the sampling size of the MPBS (13 mm²) and Licox is the same. Possibly, the oxygen consumption of the Clark electrode has less influence than expected and oxygen quenching generally measures lower values, which has been disguised in the Neurovent-PTO due to the larger sampling area.

The Paratrend/Neurotrend probe is another multiparameter catheter consisting of a fluorescent PO2 as well as ptiCO2, pH, and temperature sensors (Diametrics Medical Inc./Codman&Shurtleff) [29, 30]. This probe has been tested in brain-injured patients and showed higher values than the Licox sensor with mean differences of < 5 mm Hg [29].

Low ptiO2 values are a crucial indicator for cerebral hypoxia. Longer periods of a ptiO2 at or below 15 mm Hg were shown to increase the likelihood of death in ICU patients [31]. The agreement between MPBS and Licox in this critical ptiO2 range appears more satisfactory than in higher ptiO2 levels. The mean measurement difference in a range below 20 mm Hg was 4.0 mm Hg with almost halved limits of agreement (−9.6 to 17.7 mm Hg). The most deviating values were recorded during hyperoxygenation. Analogously, in vitro testing showed a wider distribution of MPBS values in oxygen-enriched solution. Low oxygen levels were measured with only a small variance (0.5 ± 0.1 mm Hg). The increased sensitivity of MPBS in this lower range is attributable to the fact that fluorescence lifetime is longest at low ptiO2. A direct comparison of MPBS with another oxygen quenching probe might be worthwhile.

The clinical relevance of these deviations is depicted by a dichotomized agreement matrix showing an agreement of 0.63 and 0.68 for thresholds of 15 or 20 mm Hg, respectively. Given that deviating results were mainly caused by MPBS indicating a value below and Licox a value above the threshold, ptiO2 measurement by the oxygen quenching module of MPBS might be interpreted as more conservative. Clinically, this could lead to a possible overtreatment in comparison with Licox-guided treatment as the current standard probe. On the contrary, applying, e.g., a threshold of 15 mm Hg, a Licox-induced treatment would be ‘missed’ by MPBS only in 5.8% of measurements. Further studies seem to be useful to clarify whether oxygen quenching technology might be a more sensitive technology for cerebral ischemia detection.

The temporal measurement deviation—evaluated at the baseline after hypercapnia—was higher in MPBS than in Licox. However, it is debatable whether this is attributable to a device-related drift. PtiO2 as a relatively local parameter is susceptible to environmental changes, and there might still have been an influence of the previous challenge due to disturbances in blood gases and vascular tone. Moreover, changes in the experimental setup like, e.g., brain temperature, could have affected the measurement.

The ptiO2 sensor of the MPBS exhibited improper function in 20.2% of applications. This exceeds the reported Licox error rate of 13.6% [32]. The error rate of the Neurovent-PTO ptiO2-module was reported to be 40% but was surveyed in intensive care patients and included handling errors [10]. However, Licox error rate was only 6.7% in the same setup, and accordingly, the single probe showed considerably less handling errors [10]. Dropouts in our experiments were possibly due to impairment of the catheter during implantation. Another explanation for malfunctioning could be clot creation around the tip. Such values and values linked to artificially caused measurement alteration by manipulation at the surgical site were excluded.

Evaluation of the ICP Sensor

The ICP values of the MPBS were higher than the values of the Neurovent-P probe (Raumedic) with an average difference of 2.9 mm Hg. This deviation might be partially due to methodical issues like minor calibration errors. Moreover, the different probe locations with varying physiological or surgical conditions probably also have led to divergent measurements. As displayed in the key challenges (Fig. 6), the bias was mainly based on divergent baselines, whereas the extent of reaction after provocations was quite similar. However, the limits of agreement of −7.9 to 2.1 mm Hg may imply a potential lack of both accuracy and precision.

With regard to other multiparameter probes, a comparison between the Neurovent-PTO catheter and an ICP reference probe does not exist. The ICP sensor technology is basically consistent with the Neurovent-P probe, which is already an established monitor [26]. However, confirmation of functionality also in the multiparameter
setting, which demands technical alterations, would have been of interest.

The error rate of the ICP sensor was higher in the MPBS system (15.1%) than reported in the Neurovent-PTO probe (10%) [10]. Similar to the ptiO2 module, implantation-related impairments are possible. Values collected during methodological errors due to manipulation were excluded from analysis. Moreover, sufficient calibration of some probes was not achieved in some early animals due to an improperly functioning calibration box which was replaced later. The temporal measurement deviation of MPBS was rather small.

**Evaluation of the CBF Sensor**

The comparison between the CBF sensors is based on relative flow changes since LDF cannot account for blood flow measurements in absolute terms. The change in CBF was set in relation to the baseline readings before each challenge. Altogether, the Hemedex reference probe measured 5.14% greater changes in blood flow. The linear distribution in the CBF Bland–Altman plot (Fig. 4) demonstrates a systemic bias between the two probes. Differences proportionally increase with the extent of relative change.

An advantage of intraparenchymal monitoring is that small changes can be well detected in real time. However, only a specific local area undergoes analysis. LDF can observe an area of about 1 mm³ [33]. Consequently, proximity to major vessels or implantation-associated bleeding can influence the measured CBF enormously. Therefore, varying probe insertion locations and implantation depth influence the evaluation, which attributes to the broad limits of agreement.

The deviation between the initial and late baseline was considerably high but might be rather attributed to, for example, microenvironmental changes than to a major drift, particularly given that it was present in both probes with different underlying measurement methods. From a technical point of view—at least for LDF—it should be a method with no substantial device-related drift, given that there is no membrane, electrode, or fluorophore suffering from attrition. A physiological basis for temporal changes, e.g., CBF tends to slowly increase in the aftermath of probe insertion as the microcirculation recovers from the physical insult, appears more likely. Equally, CBF can be influenced by brain temperature. Particularly Hemedex is more likely to be directly affected by environmental temperature changes. LDF would be indirectly affected by temperature-induced changes in blood flow.

The CBF module of the MPBS exhibited an error rate of 12.8%, and hence, LDF can be considered as a relatively failure-resistant technology. Indeed, the main difficulties with CBF measurement were caused by the Hemedex reference probe utilizing thermal diffusion. The Hemedex probe stopped measuring for some minutes several times during the experiments. This might have been caused by an automatic recalibration process [14]. Moreover, measurement interruption may also have been due to elevated temperatures in the measurement area and subsequent avoidance of overheating of the brain tissue by the system [34]. Retrospectively, we consider the Hemedex probe as a suboptimal reference for this study due to its lack of continuity.

**General Limitations of this Study**

A main limitation is the spatial differences between different probes. This especially affects ptiO2 and CBF measurements since ICP is a more systemic parameter. Probe location might have been in different vascular territories, and particularly CBF is influenced by the microvascular environment as described above.

Another potential source of bias is implantation depth due to differences in ptiO2 between cortical gray matter and white matter. Standardized depth was 15 mm in the experiments. However, given the different probe designs, the distance from surface to ptiO2 sampling area has varied between the different probes. As depicted in Fig. 3, the ptiO2 sampling area of the MPBS begins directly after the LDF module, whereas the distance from tip to sensitive area is 5 mm in Licox. Possibly, there were also unregistered accidental variations in depth.

Additionally, the diameters of the probes were different. This may have led to more microtrauma or microbleeding affecting the measurement in MPBS probes in comparison with Licox or Hemedex, which had smaller diameters.

As described in detail above, CBF evaluation was limited due to discontinuous measurement of the reference probe. Moreover, CBF was insufficiently challenged by the pharmacological provocations.

This study represents only a limited time frame, resulting in two limitations. First, it is possible that time from implantation to first challenge was not long enough to allow for perfect equilibration. In order to minimize this bias, stabilization of temperature and ptiO2 was awaited before starting the protocol. Second, measurement quality after days and a possible long-term drift could not have been assessed with this study.

**Conclusions**

The demonstrated in vivo data of the MPBS document the ability to measure ptiO2, CBF, and ICP in a single catheter. Even though the measured values exhibited a certain deviation in comparison with reference probes, the performance was mostly analogous to other multiparameter devices. However, further evaluation and
potential improvement of the device are necessary before it can reliably be used for clinical decision making.

Overall, the MPBS is a promising technology. Potentially, it could be a future gain for the management of brain-injured patients by enabling multiparameter neuromonitoring and allowing for new adapted therapy modalities. The suitability of the animal model and protocol for multiparameter probe evaluation were confirmed.

Electronic supplementary material
The online version of this article (https://doi.org/10.1007/s12028-018-0541-9) contains supplementary material, which is available to authorized users.

Abbreviations
CBF: Cerebral blood flow; CCI: Controlled cortical impact; CI: Cardiac index; CPP: Cerebral perfusion pressure; ICP: Intracranial pressure; LDF: Laser Doppler flowmetry; MAP: Mean arterial pressure; MPBS: Multiparameter brain sensor; PaCO₂: Arterial partial pressure of carbon dioxide; PaO₂: Arterial partial pressure of oxygen; pTO₂: Brain tissue oxygenation; TBI: Traumatic brain injury.

Author details
1 Institute for Neurosurgical Pathophysiology, University Medical Center of the Johannes Gutenberg-University, Langenbeckstr. 1, 55131 Mainz, Germany. 2 Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3 HELIOS Universitätsklinikum Wuppertal, University Witten/Herdecke, 42283 Wuppertal, Germany.

Acknowledgements
We thank A. Ehler, F. Kafai, and M. Malzahn for their technical and secretarial support during the experiments and R. Pauly from Millar Instruments and A. Obeid from Oxford Optronix for their engineering assistance.

Authors’ Contributions
MM, AL, AH, AP, PS, MM, and BA were responsible for animal experiments, data acquisition and analysis. MM, AL, OK, BA, and GW were responsible for final data analysis and manuscript preparation.

Source of Support
The study is supported by the ‘ Else Kröner-Fresenius Stiftung ’ (Homburg, Germany, study A332/2, recipient G. Wöbker). Data are part of doctoral thesis of A. Hecker, A. Leidorf, and M. M. Mader. The MPBS catheters were developed in close collaboration of Dr. A. N. Obeid (Oxford Optronix Ltd., Abingdon, UK) and R. Pauly (Millar Instruments, Houston, TX, USA) with Dr. G. Wöbker. MPBS catheters and monitors were provided by Oxford Optronix Ltd. over the period of the study.

Compliance with Ethical Standards
Conflict of interest
All authors declare no conflict of interest.

Human and Animal Rights
All applicable institutional and national guidelines for the care and use of animals were followed.

Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Published online: 11 June 2018

References
1. Parikh S, Koch M, Narayan RK. Traumatic brain injury. Int Anesthesiol Clin. 2007;45:119–35.
2. Lane PL, Skoretz TG, Doig G, Girotti MJ. Intracranial pressure monitoring and outcomes after traumatic brain injury. Can J Surg. 2000;43:442–8.
3. Bulger EM, Nathens AB, Rivara FP, Moore M, MacKenzie EJ, Jurkovich GJ. Management of severe head injury: institutional variations in care and effect on outcome. Crit Care Med. 2002;30:1870–6.
4. Valentín A, Lang T, Karnik R, Ammerer HP, Polder J, Slany J. Intracranial pressure monitoring and case mix-adjusted mortality in intracranial hemorrhage. Crit Care Med. 2003;31:1539–42.
5. Farahvar A, Gerber LM, Chiu YL, Carney N, Hartl R, Ghajar J. Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring. J Neurosurg. 2012;117:729–34.
6. McCarthy MC, Moncrief H, Sands JM, et al. Neurologic outcomes with cerebral oxygen monitoring in traumatic brain injury. Surgery. 2009;146:585–90 (discussion 590–91).
7. Narotam PK, Morrison JP, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg. 2009;111:672–82.
8. Spiotta AM, Stiefel MF, Gracies VH, et al. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg. 2010;113:571–80.
9. Namgungoo R, Maloney-Wilensky E, Stiefel M, et al. Brain tissue oxygen-directed therapy and outcome after severe traumatic brain injury: a systematic literature review. Neurocrit Care. 2012;17:131–8.
10. Huschak G, Hoell T, Hohaus C, Kern C, Minkus Y, Meisel HJ. Clinical evaluation of a new multiparameter neuromonitoring device: measurement of brain tissue oxygen, brain temperature, and intracranial pressure. J Neurosurg Anesthesiol. 2009;21:155–60.
11. Dengler J, Fenrzel C, Vajkoczy P, Wolf S, Horn P. Cerebral tissue oxygenation measured by two different probes: challenges and interpretation. Intensive Care Med. 2011;37:1809–15.
12. Doll H, Davies N, Douglas SL, et al. One sensor fits all—a new approach in monitoring brain physiology. Adv Exp Med Biol. 2009;645:175–80.
13. Leidorf A, Mader MM, Hecker A, et al. Description of the response of a new multi-parametric brain sensor to physiological and pathophysiological challenges in the cortex of juvenile pigs. Turk Neurosurg. 2014;24:913–22.
14. Rosenthal G, Sanchez-Mejia RO, Phan N, Hemphill JC 3rd, Martin C, Manley GT. Incorporating a parenchymal thermal diffusion cerebral blood flow probe in bedside assessment of cerebral autoregulation and vasoactivity in patients with severe traumatic brain injury. J Neurosurg. 2011;114:62–70.
15. Grouven U, Bender R, Ziegler A, Lange S. Comparing methods of measurement. Dtsch Med Wochenschr. 2007;132(Suppl 1):e69–73.
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.
17. Cremer OL, van Dijk GW, van Wensen E, et al. Effect of intracranial pressure monitoring and targeted intensive care on functional outcome after severe head injury. Crit Care Med. 2005;33:2207–13.
18. Shaft S, Diaz-Arrastia R, Madden C, Gentilello L. Intracranial pressure monitoring in brain-injured patients is associated with worsening of survival. J Trauma. 2008;64:335–40.
19. Haddad S, Aldwood AS, Alferayan A, Russell NA, Tamim HM, Arabi YM. Relationship between intracranial pressure monitoring and outcomes in severe traumatic brain injury patients. Anaesth Intensive Care. 2011;39:1043–50.
20. Stiefel MF, Udootuk J, Spiotta AM, et al. Conventional neurocritical care and cerebral oxygenation after traumatic brain injury. J Neurosurg. 2006;105:568–75.
21. Stiefel MF, Spiotta A, Gracies VH, et al. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitored. J Neurosurg. 2005;103:805–11.
22. Adamides AA, Cooper DJ, Rosenfeldt FL, et al. Focal cerebral oxygenation and neurological outcome with or without brain tissue oxygen-guided therapy in patients with traumatic brain injury. Acta Neurochir. 2009;151:1399–409.
23. Martini RP, Deem S, Yanez ND, et al. Management guided by brain tissue oxygen monitoring and outcome following severe traumatic brain injury. J Neurosurg. 2009;111:644–9.
24. Miller JI, Chou MW, Capocelli A, Bolognese P, Pan J, Milhorat TH. Continuous intracranial multimodality monitoring comparing local cerebral blood flow, cerebral perfusion pressure, and microvascular resistance. Acta Neurochir Suppl. 1998;71:82–4.

25. Sioutos PJ, Orozco JA, Carter LP, Weinand ME, Hamilton AJ, Williams FC. Continuous regional cerebral cortical blood flow monitoring in head-injured patients. Neurosurgery. 1995;36:943–9 (discussion 949–50).

26. Stendel R, Heidenreich J, Schilling A, et al. Clinical evaluation of a new intracranial pressure monitoring device. Acta Neurochir. 2003;145:185–93 (discussion 193)

27. Jaeger M, Soehle M, Meixensberger J. Brain tissue oxygen (PtiO2): a clinical comparison of two monitoring devices. Acta Neurochir Suppl. 2005;95:79–81.

28. Morgalla MH, Haas R, Grozinger G, et al. Experimental comparison of the measurement accuracy of the Licox((R)) and Raumedic ((R)) Neurovent-PTO brain tissue oxygen monitors. Acta Neurochir Suppl. 2012;114:169–72.

29. Sarrafzadeh AS, Kiening KL, Bardt TF, Schneider GH, Unterberg AW, Lanksch WR. Cerebral oxygenation in contusioned vs. nonlesioned brain tissue: monitoring of PtiO2 with Licox and Paratrend. Acta Neurochir Suppl. 1998;71:186–9.

30. Hoelper BM, Alessandri B, Heimann A, Behr R, Kempski O. Brain oxygen monitoring: in vitro accuracy, long-term drift and response-time of Licox-and Neurotrend sensors. Acta Neurochir. 2005;147:767–74 (discussion 774).

31. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS. Relationship of brain tissue PO2 to outcome after severe head injury. Crit Care Med. 1998;26:1576–81.

32. Dings J, Meixensberger J, Jager A, Roosen K. Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery. 1998;43:1082–95.

33. Haberl RL, Villringer A, Dirnagl U. Applicability of laser-Doppler flowmetry for cerebral blood flow monitoring in neurological intensive care. Acta Neurochir Suppl. 1993;59:64–8.

34. Jaeger M, Soehle M, Schuhmann MU, Winkler D, Meixensberger J. Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. Acta Neurochir. 2005;147:51–6 (discussion 56).

35. Timaru-Kast R, Meissner A, Heimann A, Hoelder B, Kempski O, Alessandri B. Acute subdural hematoma in pigs: role of volume on multiparametric neuromonitoring and histology. J Neurotrauma. 2008;25:1107–19.